CorrespondenceBody-mass index and metastatic melanoma outcomes
References (5)
- et al.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Lancet Oncol
(2018) - et al.
Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review
Obes Rev
(2016)
There are more references available in the full text version of this article.
Cited by (3)
A large scale meta analysis identifies common adverse events with checkpoint inhibitors vs chemotherapy in melanoma patients
2019, International ImmunopharmacologyCitation Excerpt :The data collected by the Surveillance Epidemiology and End Results from the National Cancer Institute indicated that the incidence of malignant melanoma is steadily increasing among white people, as reflected by a 60% increase in the last 3 decades [3]. Therefore, malignant melanoma has become one of the major public health issues and an important topic in cancer research [4]. There are many therapeutic approaches for melanoma.
- †
These authors contributed equally.
© 2018 Elsevier Ltd. All rights reserved.